C Bascoul-Mollevi1, S Gourgou2, M-P Galais3, J-L Raoul4, O Bouché5, J-Y Douillard6, A Adenis7, P-L Etienne8, B Juzyna9, L Bedenne10, T Conroy11. 1. Biometrics Unit - CTD INCa and French National Platform Quality of Life and Cancer, Institut Du Cancer Montpellier, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier INSERM U1194, Montpellier, France. 2. Biometrics Unit - CTD INCa and French National Platform Quality of Life and Cancer, Institut Du Cancer Montpellier, Montpellier, France. 3. Service de Pathologie digestive, Centre François Baclesse, Caen, France. 4. Service d'Oncologie médicale, Institut Paoli-Calmettes, Marseille, France. 5. Service d'Hépato-gastroentérologie et de cancérologie digestive, Centre Hospitalier Universitaire Robert Debré, Reims, France. 6. Institut de Cancérologie de l'Ouest-Centre René Gauducheau, Nantes, St Herblain, France. 7. Département d'Oncologie digestive, Centre Oscar Lambret, Lille, France. 8. CARIO, Hôpital Privé des Côtes d'Armor, Plérin, France. 9. R&D Unicancer, Paris, France. 10. Service d'Hépato-gastro-entérologie, Centre Hospitalier Universitaire François Mitterrand, Dijon, France. 11. Département d'Oncologie médicale, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; APEMAC, Université de Lorraine, Vandœuvre-lès-Nancy, France. Electronic address: t.conroy@nancy.unicancer.fr.
Abstract
BACKGROUND: A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens for inoperable non-metastatic oesophageal cancer patients. This secondary analysis aimed to describe the impact of CRT on health-related quality of life (HRQOL), physical functioning, dysphagia, fatigue and pain and to evaluate whether baseline HRQOL domains can predict overall survival. PATIENTS AND METHODS: A total of 267 patients were randomly assigned to receive with 50 Gy of radiotherapy in 25 fractions six cycles of FOLFOX or four cycles of fluorouracil and cisplatin on day 1. HRQOL was prospectively assessed using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire version 3.0 with the oesophageal cancer module (QLQ-OES18). RESULTS: Both groups showed high baseline compliance. Subsequently, compliance reduced to 41% at the 6-month follow-up. Baseline HRQOL scores showed no statistical differences between treatment arms. During treatment, both groups exhibited lower physical and social functioning and increased fatigue and dyspnoea, although dysphagia moderately improved in the fluorouracil-cisplatin arm only (p = 0.047). During follow-up, HRQOL scores revealed no significant differences between chemotherapy regimens. Linear mixed model exhibited a treatment-by-time interaction effect for dysphagia (p = 0.017) with a greater decrease in dysphagia in the fluorouracil-cisplatin group. Time until definitive deterioration analysis showed no significant differences in global HRQOL, functional or main symptom domains. However, time until definitive deterioration was significantly longer for the fluorouracil and cisplatin arm compared with FOLFOX for appetite loss (p = 0.002), QLQ-OES-18 pain (p = 0.008), trouble swallowing saliva (p = 0.011) and trouble talking (p = 0.020). CONCLUSION: Analyses of HRQOL scores revealed no statistically significant differences between patients with inoperable non-metastatic oesophageal cancer treated byFOLFOX versus those treated with a fluorouracil-cisplatin regimen as part of definitive CRT.
RCT Entities:
BACKGROUND: A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens for inoperable non-metastatic oesophageal cancerpatients. This secondary analysis aimed to describe the impact of CRT on health-related quality of life (HRQOL), physical functioning, dysphagia, fatigue and pain and to evaluate whether baseline HRQOL domains can predict overall survival. PATIENTS AND METHODS: A total of 267 patients were randomly assigned to receive with 50 Gy of radiotherapy in 25 fractions six cycles of FOLFOX or four cycles of fluorouracil and cisplatin on day 1. HRQOL was prospectively assessed using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire version 3.0 with the oesophageal cancer module (QLQ-OES18). RESULTS: Both groups showed high baseline compliance. Subsequently, compliance reduced to 41% at the 6-month follow-up. Baseline HRQOL scores showed no statistical differences between treatment arms. During treatment, both groups exhibited lower physical and social functioning and increased fatigue and dyspnoea, although dysphagia moderately improved in the fluorouracil-cisplatin arm only (p = 0.047). During follow-up, HRQOL scores revealed no significant differences between chemotherapy regimens. Linear mixed model exhibited a treatment-by-time interaction effect for dysphagia (p = 0.017) with a greater decrease in dysphagia in the fluorouracil-cisplatin group. Time until definitive deterioration analysis showed no significant differences in global HRQOL, functional or main symptom domains. However, time until definitive deterioration was significantly longer for the fluorouracil and cisplatin arm compared with FOLFOX for appetite loss (p = 0.002), QLQ-OES-18 pain (p = 0.008), trouble swallowing saliva (p = 0.011) and trouble talking (p = 0.020). CONCLUSION: Analyses of HRQOL scores revealed no statistically significant differences between patients with inoperable non-metastatic oesophageal cancer treated by FOLFOX versus those treated with a fluorouracil-cisplatin regimen as part of definitive CRT.
Authors: E Charton; B Cuer; F Cottone; F Efficace; C Touraine; Z Hamidou; F Fiteni; F Bonnetain; M-C Woronoff-Lemsi; C Bascoul-Mollevi; A Anota Journal: Qual Life Res Date: 2019-11-27 Impact factor: 4.147
Authors: Omeed Moaven; Konstantinos I Votanopoulos; Perry Shen; Paul Mansfield; David L Bartlett; Greg Russell; Richard McQuellon; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2019-11-12 Impact factor: 5.344
Authors: Audrey Winter; Benjamin Cuer; Thierry Conroy; Beata Juzyna; Sophie Gourgou; Caroline Mollevi; Célia Touraine Journal: Qual Life Res Date: 2022-09-17 Impact factor: 3.440